Direct Targeting Options for STAT3 and STAT5 in Cancer

Signal transducer and activator of transcription (STAT)3 and STAT5 are important transcription factors that are able to mediate or even drive cancer progression through hyperactivation or gain-of-function mutations. Mutated STAT3 is mainly associated with large granular lymphocytic T-cell leukemia, whereas mutated STAT5B is associated with T-cell prolymphocytic leukemia, T-cell acute lymphoblastic leukemia and γδ T-cell-derived lymphomas. Hyperactive STAT3 and STAT5 are also implicated in various hematopoietic and solid malignancies, such as chronic and acute myeloid leukemia, melanoma or prostate cancer. Classical understanding of STAT functions is linked to their phosphorylated parallel dimer conformation, in which they induce gene transcription. However, the functions of STAT proteins are not limited to their phosphorylated dimerization form. In this review, we discuss the functions and the roles of unphosphorylated STAT3/5 in the context of chromatin remodeling, as well as the impact of STAT5 oligomerization on differential gene expression in hematopoietic neoplasms. The central involvement of STAT3/5 in cancer has made these molecules attractive targets for small-molecule drug development, but currently there are no direct STAT3/5 inhibitors of clinical grade available. We summarize the development of inhibitors against the SH2 domains of STAT3/5 and discuss their applicability as cancer therapeutics.

[1]  T. Berg,et al.  Stafia‐1: a STAT5a‐Selective Inhibitor Developed via Docking‐Based Screening of in Silico O‐Phosphorylated Fragments , 2019, Chemistry.

[2]  F. D. de Sauvage,et al.  The great escape: tumour cell plasticity in resistance to targeted therapy , 2019, Nature Reviews Drug Discovery.

[3]  R. Moriggl,et al.  STAT5a/b Deficiency Delays, but does not Prevent, Prolactin-Driven Prostate Tumorigenesis in Mice , 2019, Cancers.

[4]  T. Rülicke,et al.  Structural and functional consequences of the STAT5BN642H driver mutation , 2019, Nature Communications.

[5]  Bianca Sperl,et al.  ATP Inhibits the Transcription Factor STAT5b , 2019, Chembiochem : a European journal of chemical biology.

[6]  R. Moriggl,et al.  Cell Metabolism Control Through O-GlcNAcylation of STAT5: A Full or Empty Fuel Tank Makes a Big Difference for Cancer Cell Growth and Survival , 2019, International journal of molecular sciences.

[7]  J. Rademann,et al.  The transcription factor STAT5 catalyzes Mannich ligation reactions yielding inhibitors of leukemic cell proliferation , 2019, Nature Communications.

[8]  P. Gunning,et al.  A functional in vitro assay for screening inhibitors of STAT5B phosphorylation , 2019, Journal of pharmaceutical and biomedical analysis.

[9]  A. Look,et al.  Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma , 2018, Leukemia.

[10]  Sheng Hu,et al.  A novel small inhibitor, LLL12, targets STAT3 in non-small cell lung cancer in vitro and in vivo. , 2018, Oncology letters.

[11]  Myung Ah Lee,et al.  Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma. , 2018 .

[12]  Jinxia Zhao,et al.  Stattic inhibits RANKL‐mediated osteoclastogenesis by suppressing activation of STAT3 and NF‐&kgr;B pathways , 2018, International immunopharmacology.

[13]  S. Verdura,et al.  Silibinin is a direct inhibitor of STAT3. , 2018, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[14]  S. Tsui,et al.  Natural small molecule bigelovin suppresses orthotopic colorectal tumor growth and inhibits colorectal cancer metastasis via IL6/STAT3 pathway , 2018, Biochemical pharmacology.

[15]  S. Constantinescu,et al.  Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer , 2018, Leukemia.

[16]  T. Habermann,et al.  A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers , 2018, The oncologist.

[17]  Jisung Park,et al.  Pharmacologic inhibition of STAT5 in acute myeloid leukemia , 2018, Leukemia.

[18]  C. Bock,et al.  STAT5BN642H is a driver mutation for T cell neoplasia , 2017, The Journal of clinical investigation.

[19]  S. Alkan,et al.  STAT 3 and STAT 5 A are potential therapeutic targets in castration-resistant prostate cancer , 2018 .

[20]  C. Bock,et al.  STAT 5 B N 642 H is a driver mutation for T cell neoplasia , 2018 .

[21]  S. Mustjoki,et al.  Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL , 2018, Nature Communications.

[22]  W. Leonard,et al.  Critical functions for STAT5 tetramers in the maturation and survival of natural killer cells , 2017, Nature Communications.

[23]  S. Nabavi,et al.  Targeting signal transducers and activators of transcription (STAT) in human cancer by dietary polyphenolic antioxidants. , 2017, Biochimie.

[24]  Tracy Murphy,et al.  Cytarabine and daunorubicin for the treatment of acute myeloid leukemia , 2017, Expert opinion on pharmacotherapy.

[25]  V. Poli,et al.  STAT3 in cancer: A double edged sword. , 2017, Cytokine.

[26]  M. Amin,et al.  STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer , 2017, Oncotarget.

[27]  Jisung Park,et al.  High‐throughput thermofluor‐based assays for inhibitor screening of STAT SH2 domains , 2017, Journal of pharmaceutical and biomedical analysis.

[28]  L. Pfeffer,et al.  Unphosphorylated STAT3 regulates the antiproliferative, antiviral, and gene-inducing actions of type I interferons. , 2017, Biochemical and biophysical research communications.

[29]  F. Gouilleux,et al.  New Inhibitor Targeting Signal Transducer and Activator of Transcription 5 (STAT5) Signaling in Myeloid Leukemias. , 2017, Journal of medicinal chemistry.

[30]  T. Waldmann,et al.  Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy. , 2017, Annual review of immunology.

[31]  J. Matysik,et al.  Rational development of Stafib-2: a selective, nanomolar inhibitor of the transcription factor STAT5b , 2017, Scientific Reports.

[32]  B. Groner,et al.  O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies , 2017, Leukemia.

[33]  Jeroen A. A. Demmers,et al.  The dual role of LSD1 and HDAC3 in STAT5-dependent transcription is determined by protein interactions, binding affinities, motifs and genomic positions , 2016, Nucleic acids research.

[34]  Mathias Müller,et al.  The good and the bad faces of STAT1 in solid tumours. , 2017, Cytokine.

[35]  G. Müller-Newen,et al.  Intramolecular hydrophobic interactions are critical mediators of STAT5 dimerization , 2016, Scientific Reports.

[36]  P. Baraldi,et al.  Novel iodoacetamido benzoheterocyclic derivatives with potent antileukemic activity are inhibitors of STAT5 phosphorylation. , 2016, European journal of medicinal chemistry.

[37]  K. Döhner,et al.  STAT1 activation in association with JAK2 exon 12 mutations , 2016, Haematologica.

[38]  B. Göttgens,et al.  Cytokine‐induced megakaryocytic differentiation is regulated by genome‐wide loss of a uSTAT transcriptional program , 2015, The EMBO journal.

[39]  S. Constantinescu,et al.  Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations , 2015, Current Hematologic Malignancy Reports.

[40]  E. Zandi,et al.  Hydrogen Sulfide Promotes Tet1- and Tet2-Mediated Foxp3 Demethylation to Drive Regulatory T Cell Differentiation and Maintain Immune Homeostasis. , 2015, Immunity.

[41]  Guocheng Yuan,et al.  Impact of the N-Terminal Domain of STAT3 in STAT3-Dependent Transcriptional Activity , 2015, Molecular and Cellular Biology.

[42]  Lei Gu,et al.  Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia , 2015, Molecular Cancer Therapeutics.

[43]  G. Stark,et al.  STAT3-driven transcription depends upon the dimethylation of K49 by EZH2 , 2015, Proceedings of the National Academy of Sciences.

[44]  T. Berg,et al.  Nanomolar Inhibitors of the Transcription Factor STAT5b with High Selectivity over STAT5a** , 2015, Angewandte Chemie.

[45]  Modi Wang,et al.  Discovery of a small-molecule inhibitor of STAT3 by ligand-based pharmacophore screening. , 2015, Methods.

[46]  Hua Yu,et al.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions , 2014, Nature Reviews Cancer.

[47]  P. Houghton,et al.  A Novel Small Molecular STAT3 Inhibitor, LY5, Inhibits Cell Viability, Cell Migration, and Angiogenesis in Medulloblastoma Cells* , 2014, The Journal of Biological Chemistry.

[48]  R. Moriggl,et al.  Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia , 2014, Oncotarget.

[49]  David E. Muench,et al.  Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein , 2014, ACS medicinal chemistry letters.

[50]  R. Baruchello,et al.  Inhibition of activated STAT5 in Bcr/Abl expressing leukemia cells with new pimozide derivatives. , 2014, Bioorganic & medicinal chemistry letters.

[51]  P. Furth.  STAT signaling in different breast cancer sub-types , 2014, Molecular and Cellular Endocrinology.

[52]  S. Bhattacharyya,et al.  FoxP3 acts as a cotranscription factor with STAT3 in tumor-induced regulatory T cells. , 2013, Immunity.

[53]  V. Sexl,et al.  JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. , 2013, Blood.

[54]  Yunjie Zhao,et al.  A new role for STAT3 as a regulator of chromatin topology , 2013, Transcription.

[55]  H. Land,et al.  Unphosphorylated STAT5A stabilizes heterochromatin and suppresses tumor growth , 2013, Proceedings of the National Academy of Sciences.

[56]  W. Guida,et al.  Development of new N-arylbenzamides as STAT3 dimerization inhibitors , 2013 .

[57]  Jiayuh Lin,et al.  Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design. , 2013, Journal of medicinal chemistry.

[58]  Angela G. Fleischman,et al.  TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. , 2013, Cancer discovery.

[59]  Ying Sun,et al.  Development of new N-Arylbenzamides as STAT3 Dimerization Inhibitors. , 2013, MedChemComm.

[60]  Weiliang Zhu,et al.  Discovery of novel inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening. , 2013, European journal of medicinal chemistry.

[61]  A. Koromilas,et al.  The tumor suppressor function of STAT1 in breast cancer , 2013, JAK-STAT.

[62]  W. Guida,et al.  A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation. , 2013, Cancer research.

[63]  A. Cheema,et al.  STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain , 2013, Proceedings of the National Academy of Sciences.

[64]  Ying Sun,et al.  A Novel Inhibitor of STAT 3 Homodimerization Selectively Suppresses STAT 3 Activity and Malignant Transformation , 2013 .

[65]  C. Dodge,et al.  Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma. , 2012, Oral oncology.

[66]  S. Constantinescu,et al.  The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective , 2012, JAK-STAT.

[67]  Kairong Cui,et al.  Critical Role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. , 2012, Immunity.

[68]  D. Levy,et al.  Nongenomic STAT5-dependent effects on Golgi apparatus and endoplasmic reticulum structure and function. , 2012, American journal of physiology. Cell physiology.

[69]  M. Minden,et al.  Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity. , 2012, Journal of medicinal chemistry.

[70]  B. Bernstein,et al.  Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy , 2011, Nature.

[71]  A. Dinner,et al.  Epigenetic repression of the Igk locus by STAT5-mediated recruitment of the histone methyltransferase Ezh2 , 2011, Nature Immunology.

[72]  A. Dinner,et al.  Epigenetic repression of the Igk locus by STAT5-mediated Ezh2 recruitment , 2011, Nature immunology.

[73]  B. Ebert,et al.  The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. , 2011, Blood.

[74]  G. Müller-Newen,et al.  The role of the N-terminal domain in dimerization and nucleocytoplasmic shuttling of latent STAT3 , 2009, Journal of Cell Science.

[75]  Naoki Asao,et al.  Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. , 2011, The Journal of investigative dermatology.

[76]  G. Stark,et al.  Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes , 2010, Proceedings of the National Academy of Sciences.

[77]  Lothar Hennighausen,et al.  Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden. , 2010, Neoplasia.

[78]  Kenji Matsuno,et al.  Identification of a New Series of STAT3 Inhibitors by Virtual Screening. , 2010, ACS medicinal chemistry letters.

[79]  B. Leiby,et al.  Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth. , 2010, The American journal of pathology.

[80]  Li Lin,et al.  A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. , 2010, Neoplasia.

[81]  Li Lin,et al.  New curcumin analogues exhibit enhanced growth‐suppressive activity and inhibit AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells , 2009, Cancer science.

[82]  P. Yue,et al.  Disruption of Transcriptionally Active Stat3 Dimers with Non‐phosphorylated, Salicylic Acid‐Based Small Molecules: Potent in vitro and Tumor Cell Activities , 2009, Chembiochem : a European journal of chemical biology.

[83]  D. Tweardy,et al.  Chemical Probes that Competitively and Selectively Inhibit Stat3 Activation , 2009, PloS one.

[84]  Jiayuh Lin,et al.  LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model , 2009, British Journal of Cancer.

[85]  D. Han,et al.  Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. , 2009, Cancer research.

[86]  L. Kenner,et al.  The different functions of Stat5 and chromatin alteration through Stat5 proteins. , 2008, Frontiers in bioscience : a journal and virtual library.

[87]  Judith M. Müller,et al.  A high-throughput assay for signal transducer and activator of transcription 5b based on fluorescence polarization. , 2008, Analytical biochemistry.

[88]  Judith M. Müller,et al.  Discovery of Chromone‐Based Inhibitors of the Transcription Factor STAT5 , 2008, Chembiochem : a European journal of chemical biology.

[89]  J. Boutin,et al.  4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part I: synthesis and pharmacological evaluation. , 2008, Bioorganic & medicinal chemistry letters.

[90]  L. Kenner,et al.  The different functions of Stat 5 and chromatin alteration through Stat 5 proteins , 2008 .

[91]  L. Hennighausen,et al.  STAT5 requires the N-domain to maintain hematopoietic stem cell repopulating function and appropriate lymphoid-myeloid lineage output. , 2007, Experimental hematology.

[92]  G. Stark,et al.  Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. , 2007, Genes & development.

[93]  L. Hennighausen,et al.  Direct glucocorticoid receptor-Stat5 interaction in hepatocytes controls body size and maturation-related gene expression. , 2007, Genes & development.

[94]  W. Guida,et al.  Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity , 2007, Proceedings of the National Academy of Sciences.

[95]  J. Darnell,et al.  Dephosphorylation of phosphotyrosine on STAT1 dimers requires extensive spatial reorientation of the monomers facilitated by the N-terminal domain. , 2006, Genes & development.

[96]  Bianca Sperl,et al.  Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. , 2006, Chemistry & biology.

[97]  David E Levy,et al.  STAT1 acts as a tumor promoter for leukemia development. , 2006, Cancer cell.

[98]  L. Hennighausen,et al.  Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. , 2006, Blood.

[99]  S. Becker,et al.  Structure of the Unphosphorylated STAT5a Dimer* , 2005, Journal of Biological Chemistry.

[100]  Kurt Zatloukal,et al.  Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. , 2005, Neoplasia.

[101]  M. Wasik,et al.  STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[102]  Renxiao Wang,et al.  A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[103]  Jianyuan Luo,et al.  Activation of Stat3 Sequence-specific DNA Binding and Transcription by p300/CREB-binding Protein-mediated Acetylation* , 2005, Journal of Biological Chemistry.

[104]  D. Levy,et al.  Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. , 2005, Cancer research.

[105]  E. Wagner,et al.  Stat5 tetramer formation is associated with leukemogenesis. , 2005, Cancer cell.

[106]  S. Becker,et al.  Structure of the Unphosphorylated STAT 5 a Dimer * □ , 2005 .

[107]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[108]  D. Fremont,et al.  N-domain–dependent nonphosphorylated STAT4 dimers required for cytokine-driven activation , 2004, Nature Immunology.

[109]  C. Litterst,et al.  NCoA-1/SRC-1 Is an Essential Coactivator of STAT5 That Binds to the FDL Motif in the α-Helical Region of the STAT5 Transactivation Domain* , 2003, Journal of Biological Chemistry.

[110]  J. Darnell,et al.  Signalling: STATs: transcriptional control and biological impact , 2002, Nature Reviews Molecular Cell Biology.

[111]  J. Darnell,et al.  Functional Importance of Stat3 Tetramerization in Activation of the α2-Macroglobulin Gene* , 2001, The Journal of Biological Chemistry.

[112]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[113]  S. Becker,et al.  Three-dimensional structure of the Stat3β homodimer bound to DNA , 1998, Nature.